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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, caused by various factors, 
such as the aggressiveness of the disease, the limited therapeutic options and the lack of early detection 
and risk markers. The ATP binding cassette subfamily C member 2 (ABCC2) protein plays a critical role in 
response to various drugs and is differentially expressed in gemcitabine sensitive and resistant cells. 
Moreover, Single Nucleotide Polymorphisms (SNPs) in the gene have been associated with differential 
outcomes and prognosis in several tumour types. The aim of this study was to investigate the possible 
association between SNPs in the ABCC2 gene and overall survival in PDAC patients. We analysed 12 
polymorphisms, including tagging-SNPs covering all the genetic variability of the ABCC2 gene, and 
genotyped them in 1415 PDAC patients collected within the PANcreatic Disease ReseArch (PANDoRA) 
consortium. We tested the association between ABCC2 SNPs and PDAC overall survival (OS) using Cox 
proportional hazard models. We analysed PDAC patients dividing them by stage and observed that the 
minor alleles of three SNPs showed an association with worse OS (rs3740067: HR=3.29, 95% CI 1.56-6.97, 
p=0.002, rs3740073: HR=3.11, 95% CI 1.52-6.38, p=0.002 and rs717620: HR=2.90, 95% CI 1.41-5.95, 
p=0.004 respectively) in stage I patients. In patients with more advanced PDAC we did not observe any 
statistically significant association. Our results suggest that rs3740067, rs3740073, and rs717620 could be 
promising prognostic markers in stage I PDAC patients. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/carcin/advance-article-abstract/doi/10.1093/carcin/bgz006/5281404 by Iow
a State U
niversity user on 11 January 2019
Ac
ce
pte
d M
an
us
cri
pt
3 
 
3 
 
Summary 
We investigated the possible association between SNPs in the ABCC2 gene and overall survival in 
pancreatic ductal adenocarcinoma patients and observed that the minor alleles of three SNPs showed an 
association with worse OS in stage I patients. 
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Abbreviations 
PDAC - pancreatic ductal adenocarcinoma 
ABCC2 - ATP-Binding Cassette subfamily C member 2 
SNP - single nucleotide polymorphisms 
GWAS - genome-wide association studies 
PANDoRA - PANcreatic Disease ReseArch 
OS - overall survival 
MAF - minor allele frequency 
HWE - Hardy–Weinberg equilibrium 
HR - hazard ratio 
DNMBP - Dynamin Binding Protein 
eQTL - expression quantitative trait loci  
CI - confidence interval 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an annual incidence of 12.2 
cases/100000 subjects and is the fourth most common cause of death from cancer in the European Union 
(1). PDAC showed an increasing incidence and mortality over the last several years (2). This unfavourable 
prognosis is mostly caused by the aggressiveness of the disease and the absence of specific symptoms, 
which make early diagnosis difficult. Indeed, more than half of PDAC patients have distant metastases at 
the time of diagnosis (3). Five-year survival rate for PDAC patients is 5–7% and one-year survival is achieved 
in less than 20% of the cases (4).  
Many resectable patients undergo neo-adjuvant and/or adjuvant treatment, while palliative 
chemotherapy remains the only option for almost all patients with metastatic disease (5,6). Gemcitabine is 
often employed as first-line chemotherapy regimens in these advanced cases, either as a single agent or in 
combination with Nab-paclitaxel (5). Advances in therapy using new drugs and combined drugs have only 
achieved incremental improvements in overall survival by around two months. Several studies suggest 
differential effectiveness in subsets of patients, so that the current practice may increase toxicity without 
increasing efficacy for many patients, and can provide notable benefit for undefined subgroups of patients 
(5–7). As a consequence, there is an urgent need for better understanding the pharmacogenetics of PDAC 
in order to improve patient selection for current treatment options. Several studies focused on the role of 
ATP-binding cassette (ABC) genes in pancreatic cancer chemoresistance, considering both their expression 
or their genetic variability (8–12).  
In particular, a study reporting on the differential gene expression between cells sensitive and 
resistant to gemcitabine showed the differential expression of the ATP-Binding Cassette subfamily C 
member 2 (ABCC2) gene (13). ABCC2, also known as multi-drug resistance protein 2 (MRP2), plays a role in 
detoxification and chemoprotection, transporting several xenobiotic compounds outside the cell and 
modulating the pharmacokinetics of many drugs (14). Several studies showed that single nucleotide 
polymorphisms (SNPs) of the ABCC2 gene are associated with altered distribution, metabolism, and 
elimination of a plethora of drugs (15–19). The possible influence of the genetic background in survival of 
PDAC patients has been suggested by a number of studies including five genome-wide association studies 
(GWAS) (20–28). Considering that ABCC2 may be involved in the process of response to therapy, in this 
study we tested the possible association between the genetic variants in the ABCC2 gene and the survival 
of PDAC patients. 
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Materials and methods 
Study population 
This study was conducted within the PANcreatic Disease ReseArch (PANDoRA) consortium, described 
in detail elsewhere (29). PDAC patients (n=1415) were collected in 7 European countries (Italy, Germany, 
Hungary, Czech Republic, Poland, Lithuania, United Kingdom). For each patient, information about the 
country of origin, cancer staging (according to American Joint Committee on Cancer TNM system 7th 
version), gender and age at diagnosis was collected. Furthermore, detailed information concerning overall 
survival (OS) was recorded as well. 
The characteristics of patients are described in Table I.  
 
Ethics statement 
All subjects signed a written consent form. Ethical approval for the PANDoRA study protocol was 
received from the Ethics Commission of the Medical Faculty of the University of Heidelberg (S-565/2015). 
 
Selection of genes and polymorphisms 
We utilised a tagging SNP approach. The entire set of common genetic variants, with minor allele 
frequency (MAF) ≥5% in Caucasians was downloaded from the International HapMap Project (30). Tagging 
SNPs were selected using the Tagger algorithm available through Haploview (31), using pairwise SNP 
selection with a minimum r2 threshold of 0.8. This process resulted in a selection of 12 tagging SNPs for 
ABCC2, with a mean r2 of the selected SNP with the SNPs they tag of 0.981. This selection, therefore, 
captures a very high degree (over 95%) of the known common variability in ABCC2. The 12 SNPs selected 
are shown in Table II. 
 
DNA extraction and genotyping 
Blood was collected using standard EDTA collection tubes and stored at -20C° until DNA isolation. DNA 
was extracted from whole blood using the Qiagen mini kit (Qiagen, Hilden, Germany) or the All-Prep 
Isolation kit (Qiagen) according to the manufacturer's protocol. Both kits are standard spin column 
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extraction methods. For better standardization of the procedure the DNA was isolated using the QIAcube 
instrument (Qiagen, Hilden, Germany). DNA concentration was checked with a spectrophotometer and 
purity was assessed with the ratio of absorbance at 260nm and 280nm. DNA was then stored at -20C° until 
use at the German Cancer Research Center in Heidelberg. Genotyping was performed using the allele-
specific KASP genotyping system (KBiosciences, Hoddesdon, UK) as recommended by the manufacturer 
which is a competitive PCR based on fluorescent resonance energy transfer (FRET) principle. Each 384-well 
plate was prepared to contain a minimum of 8 (2%) negative controls (i.e. wells in which every reagent was 
used except for the DNA template) and around 9% of the samples were duplicated, for quality control. The 
order of DNA samples of cases and controls was randomised on the plates. PCR plates were read on a ViiA7 
real-time instrument (Applied Biosystems, Foster City, California, United States) and FLUOstar® Omega 
sequence detection system (BMG LABTECH Ortenberg, Germany). The ViiA7 RUO Software, version 1.2.2 
(Applied Biosystems) and the KlusterCaller software (LGC, Teddington, UK), were used to determine 
genotypes.  
 
Statistical analysis 
The observed genotype frequencies of all SNPs in PDAC cases were tested for deviation from Hardy–
Weinberg equilibrium (HWE) using Pearson’s chi-square test. Overall survival (OS) was defined as the time 
interval between PDAC diagnosis and death or the last date when the patient was still alive. Association 
with OS was calculated as hazard ratio (HR) using Cox regression multivariate analysis adjusted for age, 
gender, country of origin and stage of PDAC. Association estimates were calculated according to dominant 
and co-dominant models of inheritance with the major allele as a reference. We also performed a stratified 
analysis by stage to evaluate the associations between SNPs and OS in different PDAC progression stages. 
In order to take into account multiple comparisons, we calculated the effective number of 
independent genetic markers (N=8) using the (Meff) method by the spectral decomposition (SpD) of 
matrices of pairwise LD between SNPs (32,33). The critical value for statistical significance was corrected by 
the Bonferroni method to a significance threshold of p=0.006 (0.05/8).  
 
Bioinformatic analysis  
We used several bioinformatic tools to assess the possible functional relevance for the SNP showing 
the most significant association with OS. RegulomeDB (http://regulome. stanford.edu/)  and HaploReg v4.1 
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(http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) was used to identify the regulatory 
potential of the region nearby each SNP (34,35). The GTEx portal web site (http://www.gtexportal.org) was 
used to identify potential associations between the SNPs and expression levels of nearby genes (eQTL) (36). 
Additionally, we used the SNAP software (http://archive.broadinstitute.org/mpg/snap/)  to find SNPs in LD 
with the SNP that showed the strongest association with OS using a threshold of r2 = 0.70 (37). 
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Results 
All the selected SNPs were in HWE (p>0.05) in our study population. The genotyping concordance 
between duplicate samples (N=130) exceeded 99% and the average SNP call rate was 96% (92%–99%). 
We did not observe any statistically significant association when considering all patients together 
(Supplementary table I). We repeated the analyses stratifying by stage, given that it strongly influences 
survival. Three polymorphisms (rs3740067, rs3740073, rs717620) were found to have a statistically 
significant association (P<0.006) with PDAC survival in patients in stage I. Specifically, we observed an 
association with shorter OS for the G allele of the rs3740067 SNP (HRdom=3.29, 95% CI 1.56-6.97, p=0.002), 
the T allele of the rs3740073 SNP (HRdom=3.11, 95% CI 1.52-6.38, p=0.002) and the T allele of the rs717620 
SNP (HRdom=2.90, 95% CI 1.41-5.95, p=0.004) (Table III). Figure 1 shows the Kaplan-Meier curves for the 
association between ABCC2 SNPs-(rs3740067, rs3740073, rs717620) and OS for patients in stage I. Kaplan-
Meier curves for all patients are shown in supplementary figure 1. Additionally, we analyzed jointly 
patients in stage I and II, but we did not observe any statistically significant association (data not shown). 
We analysed the SNPs showing the most significant associations using bioinformatic tools to predict 
the possible biological functions. The three significant SNPs showed different scores in RegulomeDB. 
Specifically, rs3740067 has a score of 3a, indicating the possible presence of a transcription factor binding 
motif, a DNase sensitivity peak, and any protein motif alteration, a score of 6 for rs3740073 indicates the 
absence of annotations and 4 for rs717620 indicates the possible presence of a transcription factor binding 
motif and a DNase sensitivity peak.  
GTEx (36) shows that rs3740067, rs3740073, and rs717620 alter the expression of four 
genes: ABCC2, Dynamin Binding Protein (DNMBP), DNMBP Antisense RNA 1 (DNMBP-AS1) and 
CWF19 Like 1 (CWF19L1) in eighteen different tissues (Supplementary table II). 
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Discussion 
PDAC shows a mortality rate that is very similar to the incidence and it is estimated that by 2030 it will 
be the second cancer for mortality (38). A possible way to improve treatment efficacy could be to consider 
the genetic background of the patients and possibly tailor a personalized treatment. There is convincing 
evidence pointing to a possible role of ABCs genes in PDAC drug resistance. For instance, Konig and 
colleagues examined the expression level of nine ABC genes in normal and tumoral pancreatic tissues, 
finding the majority of them to be expressed. Schaarschmidt reported the expression of ABCB1 and ABCC2 
genes in both normal and inflamed pancreatic tissue (9,12). In a recent paper Huang and colleagues 
proposed a possible association between ABCC2 expression and gemcitabine sensitiv ty (8). Genetic 
variants in transporter pumps could influence the quantity of drugs that reaches the target and the time 
that the drug remains in the cell to exert its effect. For example, Pang and colleagues found that a 
particular haplotype in the ABCB1 gene was associated with increased gemcitabine sensitivity (11). Tanaka 
and collaborators observed several associations between ABC gene variants and PDAC outcome (10). In our 
study we focused on the polymorphisms of ABCC2, an ATP dependent efflux pump that has been 
investigated in many pharmacogenetics studies given its central role in drug transport and excretion.  
Considering all 1415 PDAC cases together we observed no statistically significant association between 
the 12 selected SNPs and disease outcome, however when stratifying for stage we identified three 
polymorphisms showing an association with OS in stage I patients. In particular, we observed statistically 
significant associations between rs3740067 (p=0.002), rs3740073 (p=0.002) and rs717620 (p=0.004) and 
shorter survival. The rs3740067 and rs3740073 polymorphisms have already been studied in the context of 
studies on risk of various cancers and survival, but did not show significant associations (39,40). Tanaka et 
al (10) performed an investigation on ABCs genes SNPs on 154 ethnically diverse pancreatic cancer 
patients. Two ABCC2 SNPs were included in that study. The major allele of rs2273697 was associated with 
decreased survival and with worse response to therapy. We have used SNP rs11190291, which is in perfect 
LD (r2=1) with rs2273697. In our data rs11190291 does not show a statistical significance overall, but the 
major allele is consistently associated with worse survival, and when analyzing only the stage IV patients it 
reaches a nominal significance (p=0.015). The other SNP analyzed by Tanaka and colleagues, rs3740066, is 
in perfect LD with our SNP rs3740067. Also for these SNPs the association goes in the same direction (minor 
allele of both SNPs associated with worse survival) although in our data the association is significant if 
considering stage I patients, but not in the overall population. In the report by Tanaka and colleagues this 
SNP does not show any significant association. Overall, the direction of associations seems to be consistent 
between the two reports, however the rather small numbers used by Tanaka did not allow them to 
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perform stratified analysis and therefore the two results are not directly comparable. On the other hand, 
despite it has never been studied in relation to PDAC patient survival, ABCC2-rs717620 is a potentially 
functional SNP situated in the promoter region of the gene. In a relatively large study on lung cancer 
survival the T allele of the rs717620 has been associated with shorter progression-free survival (19). 
Furthermore the minor allele (T) was associated with increased risk of neurological toxicity in cancer 
patients treated with the 5-fluorouracil, and with increased platinum-related toxicity in lung cancer 
patients (41,42). Increased sensitivity to the toxic effects of chemotherapeutic agents can lead to 
premature discontinuation of therapy, reducing the patient's chances of survival. All these reports are in 
agreement with the results emerging from the present study, suggesting a worse prognosis for carriers of 
the T allele of ABCC2-rs717620. It is noteworthy that the polymorphism seems to have a stronger effect on 
the first stages of the disease, since in lung cancer it is associated with progression-free survival and in our 
study with a differential survival in stage I patients. Considering the function of the protein, i.e. exporting 
xenobiotics from the cells, it is plausible that an altered expression could be associated with a decreased 
drug efficacy and/or with an increase in toxicity. Using several bioinformatic tools such as GTEx we tested in 
silico this hypothesis, however the tools did not provide straightforward results. For example the regulome 
DB score was 4, indicating a possible presence of a transcription factor binding motif or a DNase sensitivity 
peak, however GTEx did not identify any eQTLs for ABCC2-rs717620 in the pancreas.  
According to GTEx the three alleles associated with shorter survival are associated with the increased 
expression of DNMBP in several tissues, but not in the pancreas. DNMBP is a gene that codes for a scaffold 
protein for dynamines that are involved in scission of newly formed vesicles from the membranes. 
Functional studies suggest that dynamin proteins can participate in promoting cell migration and 
metastasis in PDAC cellular and mouse models (43,44). In addition, in a recent study, dynamins and their 
complexes have been hypothesized as important therapeutic targets in cancer (45). The association 
between aggressiveness of cancers and expression of dynamins and their protein complexes is well 
matched with our data, where the alleles associated with decreased survival are associated with an 
increase in DNMBP gene expression, as shown in GTEx. In light of the fact that the GTEx associations 
between SNPs and gene expression are not observed in the pancreatic tissue, these results need to be 
taken with caution. However it is potentially interesting to note that in all the tissues present in GTEx the 
associations between alleles and gene expression seems to be consistent (i.e. the minor alleles are always 
associated with increased expression). Based on these observations we can hypothesize that the 
association is the same in the pancreas. 
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One of the major strengths of this study is its size, since with a total of 1415 subjects it is one of the 
largest on pancreatic cancer survival. Additionally, our selection of SNPs provides a wide coverage of 
genetic variability in the ABCC2 gene region. 
A possible limitation of our study is not having the information regarding the therapies to which the 
patients were subjected. This type of data could have producted greater value to the associations and their 
possible biological functions. In addition, the associations that we find significant have been identified in a 
small subgroup of patients. The vast majority of the patients enrolled in this study (83%) received surgery 
and therefore it is not possible to generalize our findings. Moreover, all study subjects were Europeans and 
it is not possible to generalize our findings to other ethnic groups. 
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Conclusion 
In conclusion, our study showed three promising polymorphisms associated with overall survival in 
stage I pancreatic cancer patients. The polymorphic variant of the promoter (rs717620) has been already 
found to be associated with survival in cancer patients, supporting our findings, even though a biological 
explanation remains elusive. Finding an association in the early stage of the cancer is potentially interesting 
because treatment could have a greater impact on the disease outcome. 
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Table I. Information about the patients from PANDoRA consortium analysed in our study. 
 PDAC cases 
Country/region  
Germany 410 
Northern Italy 343 
Central Italy 80 
Southern Italy 43 
Hungary 195 
Czech Republic 146 
United Kingdom 73 
Poland 72 
Lithuania 53 
Total 1415 
  
Sex  
Male 57.4% 
Female 42.6% 
  
Median age 65.5 
(25th – 75th percentile) 58.5-72.0 
  
Median OS in months 11.77 
  
Stage (median OS in months) 
[percentage of patients operated] 
 
I 88 (15.50) [97%] 
II 748 (14.50) [98%] 
III 145 (10.55) [86%] 
IV 434 (8.51) [74%] 
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Table II. Annotation of the ABCC2 gene selected SNPs  
SNP Position on chr 10 A Alleles MAF B Consequence 
rs717620 99782821 C>T T=20% Non Coding Transcript Variant 
rs7393105 99787264 C>A C=44% Intron Variant 
rs4148388 99790008 G>A G=41% Intron Variant 
rs2756109 99798989 G>T G=43% Intron Variant 
rs11190291 99806253 C>T T=20% Intron Variant 
rs3740073 99817203 T>C T=39% Intron Variant 
rs4077146 99829571 G>A A=25% Intron Variant 
rs7476245  99834972 G>A A=5% Intron Variant 
rs3740067 99844024 C>G G=37% Intron Variant 
rs3740065 99845936 A>G G=12% Intron Variant 
rs8187710 99851537 G>A A=7% Missense Variant (Cys>Tyr) 
rs11190297 99858346 G>T T=6% None 
 
A Genome Reference Consortium Human Build 38 patch release 7 (GRCh38.p7) 
B Minor Allele Frequency; 1000Genomes_EUR 
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Table III. Cox analysis stratified by stage of the three polymorphisms significantly associated (P<0.006) with OS. 
SNP Genotype Stage I Stage II Stage III Stage IV 
N HR 95% CI P N HR 95% CI P N HR 95% CI P N HR 95% CI P 
rs3740067 CC 29 1 - - 293 1 - - 69 1 - - 149 1 - - 
 CG 39 3.07 (1.41-6.68) 0.0046 340 0.99 (0.82-1.19) 0.8829 57 0.86 (0.55-1.35) 0.5248 193 1.17 (0.92-1.49) 0.1899 
 GG 12 4.16 (1.6-10.86) 0.0035 102 0.98 (0.75-1.27) 0.8535 15 0.76 (0.39-1.5) 0.4314 55 1.22 (0.86-1.72) 0.2686 
 dom  3.29 (1.56-6.97) 0.0018  0.98 (0.83-1.17) 0.8532  0.84 (0.55-1.28) 0.414  1.18 (0.94-1.48) 0.1475 
 Total 80    735    141    397    
rs3740073 CC 29 1 - - 262 1 - - 58 1 - - 144 1 - - 
 CT 43 3.11 (1.46-6.61) 0.0032 339 0.93 (0.77-1.12) 0.4337 57 1.32 (0.84-2.05) 0.2259 178 1.24 (0.98-1.58) 0.0727 
 TT 13 3.12 (1.26-7.7) 0.0137 105 1.12 (0.86-1.47) 0.3908 15 0.72 (0.33-1.54) 0.3956 58 1.2 (0.85-1.69) 0.295 
 dom  3.11 (1.52-6.38) 0.0019  0.97 (0.81-1.16) 0.7143  1.16 (0.76-1.79) 0.4839  1.23 (0.98-1.54) 0.0685 
 Total 85    706    130    380    
rs717620 CC 50 1 - - 429 1 - - 89 1 - - 230 1 - - 
 CT 24 2.8 (1.34-5.86) 0.0061 199 1.09 (0.9-1.34) 0.3747 40 0.78 (0.47-1.31) 0.3521 135 1.12 (0.88-1.43) 0.3473 
 TT 2 5.78 (0.36-93.9) 0.2171 26 0.73 (0.45-1.18) 0.2023 2 4.35 (0.99-19.18) 0.052 12 0.99 (0.53-1.85) 0.9772 
 dom  2.9 (1.41-5.95) 0.0038  1.04 (0.86-1.26) 0.6967  0.84 (0.51-1.38) 0.4885  1.11 (0.88-1.4) 0.3843 
 Total 76    654    131    377    
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HR: hazard ratio; CI: confidence interval; P: p-value; dom: dominant model.
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Figure legends 
Figure 1. Kaplan Meier survival analysis. 
Kaplan Meier survival curves of three polymorphisms (A) rs3740067, (B) rs3740073, (C) rs717620 were 
found to have a statistically significant association with PDAC survival in patients in stage I. 
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